$TCRT
Alaunos Therapeutics, Inc.

2013 Q2 Form 10-Q Financial Statement

#000119312513204366 Filed on May 07, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2013 Q1 2012 Q1
Revenue $200.0K $200.0K $200.0K
YoY Change 0.0% 0.0% 198.51%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.720M $4.670M $4.850M
YoY Change -24.08% -3.71% 44.78%
% of Gross Profit
Research & Development $14.78M $19.11M $13.99M
YoY Change -19.1% 36.66% -20.09%
% of Gross Profit
Depreciation & Amortization $200.0K $200.0K $120.0K
YoY Change 33.33% 66.67% 200.0%
% of Gross Profit
Operating Expenses $14.78M $19.11M $13.99M
YoY Change -19.1% 36.66% -20.09%
Operating Profit -$18.30M -$23.58M -$18.63M
YoY Change -20.33% 26.57% -33.28%
Interest Expense -$400.0K $10.79M -$5.810M
YoY Change -38.46% -285.71% -47.56%
% of Operating Profit
Other Income/Expense, Net $7.000K -$4.000K -$26.00K
YoY Change 133.33% -84.62% 1200.0%
Pretax Income -$18.69M -$12.80M -$24.47M
YoY Change -20.84% -47.69% -37.27%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$18.69M -$12.80M -$24.47M
YoY Change -20.84% -47.7% -37.27%
Net Earnings / Revenue -9346.0% -6399.5% -12235.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.22 -$0.15 -$0.32
COMMON SHARES
Basic Shares Outstanding 83.56M shares 83.70M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.90M $55.70M $128.0M
YoY Change -64.76% -56.48% 3.23%
Cash & Equivalents $38.93M $55.66M $128.0M
Short-Term Investments
Other Short-Term Assets $4.100M $4.800M $10.80M
YoY Change -54.95% -55.56% 1100.0%
Inventory
Prepaid Expenses
Receivables $0.00 $100.0K $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $43.03M $60.56M $138.8M
YoY Change -63.96% -56.37% 6.78%
LONG-TERM ASSETS
Property, Plant & Equipment $1.713M $1.909M $1.177M
YoY Change -14.35% 62.19% 194.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $732.0K $743.0K $794.0K
YoY Change -26.8% -6.42% 98.5%
Total Long-Term Assets $2.573M $2.785M $2.062M
YoY Change -14.23% 35.06% 129.11%
TOTAL ASSETS
Total Short-Term Assets $43.03M $60.56M $138.8M
Total Long-Term Assets $2.573M $2.785M $2.062M
Total Assets $45.60M $63.35M $140.9M
YoY Change -62.74% -55.03% 7.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.165M $983.0K $1.984M
YoY Change -22.33% -50.45% 4.42%
Accrued Expenses $18.97M $18.52M $11.53M
YoY Change 22.38% 60.58% 195.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.00M $20.36M $14.33M
YoY Change 17.96% 42.09% 120.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.576M $2.174M $25.19M
YoY Change -91.12% -91.37% -40.58%
Total Long-Term Liabilities $2.576M $2.174M $25.19M
YoY Change -91.12% -91.37% -40.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.00M $20.36M $14.33M
Total Long-Term Liabilities $2.576M $2.174M $25.19M
Total Liabilities $26.27M $25.45M $43.17M
YoY Change -43.75% -41.04% -11.71%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $330.8M $327.6M $302.7M
YoY Change 8.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.33M $37.89M $97.70M
YoY Change
Total Liabilities & Shareholders Equity $45.60M $63.35M $140.9M
YoY Change -62.74% -55.03% 7.62%

Cashflow Statement

Concept 2013 Q2 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$18.69M -$12.80M -$24.47M
YoY Change -20.84% -47.7% -37.27%
Depreciation, Depletion And Amortization $200.0K $200.0K $120.0K
YoY Change 33.33% 66.67% 200.0%
Cash From Operating Activities -$16.72M -$18.24M -$25.86M
YoY Change -0.3% -29.45% 216.64%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $114.0K $154.0K
YoY Change -98.96% -25.97% -32.16%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities -$10.00K -$114.0K -$154.0K
YoY Change -98.96% -25.97% -32.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $246.0K $52.60M
YoY Change -99.53% -556.52%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 706.0K 49.31M
YoY Change -100.0% -98.57% -31.55%
NET CHANGE
Cash From Operating Activities -16.72M -18.24M -25.86M
Cash From Investing Activities -10.00K -114.0K -154.0K
Cash From Financing Activities 0.000 706.0K 49.31M
Net Change In Cash -16.73M -17.65M 23.30M
YoY Change -5.1% -175.77% -63.4%
FREE CASH FLOW
Cash From Operating Activities -$16.72M -$18.24M -$25.86M
Capital Expenditures $10.00K $114.0K $154.0K
Free Cash Flow -$16.73M -$18.36M -$26.01M
YoY Change -5.64% -29.43% 209.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2006Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
5.09
CY2007Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
5.75
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
83562779 shares
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
128008000
CY2013Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4834000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1624587 shares
CY2013Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
327495000
CY2013Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
743000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3408985 shares
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
37893000
CY2013Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8800000
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
801000
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.85
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
801000
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83680849 shares
CY2013Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11148139 shares
CY2013Q1 us-gaap Other Additional Capital
OtherAdditionalCapital
6837000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
6693959 shares
CY2013Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
72000
CY2013Q1 us-gaap Liabilities
Liabilities
25453000
CY2013Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
983000
CY2013Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
800000
CY2013Q1 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
296523000
CY2013Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2174000
CY2013Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2013Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
54550000
CY2013Q1 us-gaap Assets
Assets
63346000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.26
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
3.85
CY2013Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
133000
CY2013Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
63346000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
795000
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55655000
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83680849 shares
CY2013Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18521000
CY2013Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
58000
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
20362000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6743835 shares
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
84000
CY2013Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
384000
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2533000
CY2013Q1 us-gaap Assets Current
AssetsCurrent
60561000
CY2013Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
325177000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1001000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3683786 shares
CY2013Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1909000
CY2013Q1 ziop Warrant Liabilities Fair Value Disclosure
WarrantLiabilitiesFairValueDisclosure
2174000
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Expected Life
ClassOfWarrantOrRightFairValueAssumptionExpectedLife
5 Y
CY2009Q4 ziop Class Of Warrant Term
ClassOfWarrantTerm
P5Y
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield
ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield
0.00 pure
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Stock Volatility
ClassOfWarrantOrRightFairValueAssumptionStockVolatility
1.05 pure
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate
ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate
0.0214 pure
CY2009Q4 ziop Estimated Fair Value Of Warrant
EstimatedFairValueOfWarrant
22900000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104713000
CY2012Q1 ziop Common Stock Price Per Share1
CommonStockPricePerShare1
5.20
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6912000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
48445000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3972000
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.56
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83236840 shares
CY2012Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11197454 shares
CY2012Q4 us-gaap Other Additional Capital
OtherAdditionalCapital
6909000
CY2012Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
58000
CY2012Q4 us-gaap Liabilities
Liabilities
34959000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1509000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
800000
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
283724000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12962000
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2012Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
72002000
CY2012Q4 us-gaap Assets
Assets
83404000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.11
CY2012Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
133000
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83404000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73306000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83236840 shares
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16516000
CY2012Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
39000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18864000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7147303 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
83000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
983000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4697000
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
400000
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2733000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
80276000
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1994000
CY2012Q4 ziop Warrant Liabilities Fair Value Disclosure
WarrantLiabilitiesFairValueDisclosure
12962000
CY2006Q2 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2013-05-03
CY2006Q2 ziop Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
706708 shares
CY2007Q1 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2012-02-23
CY2007Q1 ziop Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
1359317 shares
us-gaap Operating Income Loss
OperatingIncomeLoss
-322779000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
21559000
us-gaap Contracts Revenue
ContractsRevenue
1667000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
21559000
us-gaap Share Based Compensation
ShareBasedCompensation
21722000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
324446000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
352000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3113000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2773000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2224000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-239883000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4739000
us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3333000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4740000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
55655000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
442000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
92989000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4834000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
13180000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
231457000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
300277000
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
500000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
134000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-57000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
743000
us-gaap Interest Paid
InterestPaid
ziop Issuance Of Warrants To Placement Agent In Public Offering
IssuanceOfWarrantsToPlacementAgentInPublicOffering
47276000
CY2009 ziop Warrants To Purchase Aggregate Shares Of Common Stock
WarrantsToPurchaseAggregateSharesOfCommonStock
8206520 shares
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M11D
CY2012 ziop Milestone Payment Under License Agreement
MilestonePaymentUnderLicenseAgreement
250000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
36151000
us-gaap Net Income Loss
NetIncomeLoss
-296523000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
72000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
16760000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
18521000
ziop Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
270726000
CY2013Q1 dei Document Type
DocumentType
10-Q
CY2013Q1 dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
CY2013Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001107421
CY2013Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52600000
CY2012Q1 ziop Common Stock Shares Sold
CommonStockSharesSold
10114401 shares
CY2013Q1 dei Trading Symbol
TradingSymbol
ZIOP
CY2013Q1 dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
CY2013Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-23583000
CY2013Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
10788000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-526000
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M11D
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
CY2013Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1541000
CY2013Q1 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2013Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
10788000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y3M11D
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0100 pure
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1541000
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.72
CY2013Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
23783000
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.88
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2013Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
453168 shares
CY2013Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
246000
CY2013Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
246000
CY2013Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
199000
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2013Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
851000
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18243000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-114000
CY2013Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-200000
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.88
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
114000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-17651000
CY2013Q1 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
3000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8340 pure
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4671000
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2078000
CY2013Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M1D
CY2013Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
851000
CY2013Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
101000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19112000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
706000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
61200 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8369 pure
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M23D
CY2013Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-258000
CY2013Q1 us-gaap Interest Paid
InterestPaid
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
82906080 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0115 pure
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18494042 shares
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-12799000
CY2013Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
14000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
110900 shares
CY2012Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26000
CY2012Q1 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2005000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.32
CY2013Q1 ziop Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
101000
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18633000
CY2012Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-5811000
CY2012Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
257000
CY2012Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-5811000
CY2012Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2012Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0111 pure
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1212000
CY2012Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
18833000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2012Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
42000
CY2012Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
118000
CY2012Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25860000
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-154000
CY2012Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2012Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-200000
CY2012Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
154000
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
23295000
CY2012Q1 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
133000
CY2012Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8348 pure
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4848000
CY2012Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9490000
CY2012Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
140000
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13985000
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49309000
CY2012Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8353 pure
CY2012Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
23000
CY2012Q1 us-gaap Interest Paid
InterestPaid
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
75620130 shares
CY2012Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0113 pure
CY2012Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17898822 shares
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-24470000
CY2012Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-79000
CY2012Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
63500 shares
CY2012Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
713000
CY2012Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.31
CY2012Q1 ziop Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
49169000
CY2012Q1 ziop Reclassification Of Warrant Liabilities To Equity
ReclassificationOfWarrantLiabilitiesToEquity
42000

Files In Submission

Name View Source Status
0001193125-13-204366-index-headers.html Edgar Link pending
0001193125-13-204366-index.html Edgar Link pending
0001193125-13-204366.txt Edgar Link pending
0001193125-13-204366-xbrl.zip Edgar Link pending
d527262d10q.htm Edgar Link pending
d527262dex311.htm Edgar Link pending
d527262dex312.htm Edgar Link pending
d527262dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20130331.xml Edgar Link completed
ziop-20130331.xsd Edgar Link pending
ziop-20130331_cal.xml Edgar Link unprocessable
ziop-20130331_def.xml Edgar Link unprocessable
ziop-20130331_lab.xml Edgar Link unprocessable
ziop-20130331_pre.xml Edgar Link unprocessable